Running out of reconstituted peptide mid-protocol and having to reconstitute a new vial introduces batch-to-batch variability
Key evidence includes: Gastric emptying studies (also called gastric scintigraphy) showing delayed stomach emptying, which is the gold standard test for diagnosing gastroparesis Medical records documenting your GLP-1 prescription, dosage, duration of use, and the timeline of when symptoms began Emergency room records if you sought treatment for severe nausea, vomiting, dehydration, or intestinal blockage Hospitalization records, if you required inpatient treatment for GI complications Diagnostic imaging, such as upper GI series, CT scans, or MRIs, showing intestinal problems Endoscopy or colonoscopy results, if performed to evaluate your symptoms Pharmacy records showing when you filled prescriptions and how long you used the medication Documentation of treatments, including medications for nausea, dietary changes, or surgical interventions If you experienced severe symptoms consistent with gastroparesis but havent undergone gastric emptying studies, talk to your healthcare provider about appropriate testing
Discontinue Ozempic or Rybelsus tablets in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide Lactation: A clinical lactation study reported semaglutide concentrations below the lower limit of quantification in human breast milk
Children 4(6):46 Arroyave-Ospina JC, Wu Z, Geng Y, Moshage H (2021) Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: implications for prevention and therapy
Stratified analyses showed no differences between subgroups
"Some studies have shown that consuming too much fat can increase symptoms of fullness, nausea, and bloating in individuals with digestive issues and heartburn
